Characteristics and Outcomes of Thrombolysis-Treated Stroke Patients With and Without Saccular Intracranial Aneurysms.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
12 2022
Historique:
pubmed: 19 10 2022
medline: 1 12 2022
entrez: 18 10 2022
Statut: ppublish

Résumé

Intravenous thrombolysis seems safe in acute ischemic stroke patients with saccular, unruptured intracranial aneurysms (UIAs), but little is known about the differences in cardiovascular risk factors and outcomes between intravenous thrombolysis-treated stroke patients with and without UIAs. We hypothesized that UIA patients would have a higher burden of cardiovascular risk factors and, therefore, a higher risk of an unfavorable outcome. In this prospective cohort study conducted in Helsinki University Hospital, we identified intravenous thrombolysis-treated patients with concurrent saccular UIAs admitted to a comprehensive stroke center between 2005 and 2019 using 2 overlapping methods. For each UIA patient, a control patient was identified and matched (1:1) for age, sex, admission year, and stroke severity. The primary outcome was an unfavorable outcome at 3 months, defined as a modified Rankin Scale (mRS) score 3 to 6. The secondary outcomes were an excellent outcome (mRS score 0-1) at 3 months and mRS difference in shift analysis. In total, 118 UIA patients and 118 matched control patients were identified. The UIA patients were more often current smokers, and their admission systolic blood pressure was higher. The rate of hemorrhagic complications did not differ between the groups. UIAs were not associated with an unfavorable outcome in the conditional logistic regression analysis (odds ratio, 1.41 [95% CI, 0.79-2.54]; The intravenous thrombolysis-treated stroke patients with UIAs were more often current smokers and had higher systolic blood pressure than the matched patients without UIAs. They were as likely to have unfavorable outcomes at 3 months but seemed less likely to achieve excellent outcomes and were more likely to have higher mRS in shift analysis.

Sections du résumé

BACKGROUND
Intravenous thrombolysis seems safe in acute ischemic stroke patients with saccular, unruptured intracranial aneurysms (UIAs), but little is known about the differences in cardiovascular risk factors and outcomes between intravenous thrombolysis-treated stroke patients with and without UIAs. We hypothesized that UIA patients would have a higher burden of cardiovascular risk factors and, therefore, a higher risk of an unfavorable outcome.
METHODS
In this prospective cohort study conducted in Helsinki University Hospital, we identified intravenous thrombolysis-treated patients with concurrent saccular UIAs admitted to a comprehensive stroke center between 2005 and 2019 using 2 overlapping methods. For each UIA patient, a control patient was identified and matched (1:1) for age, sex, admission year, and stroke severity. The primary outcome was an unfavorable outcome at 3 months, defined as a modified Rankin Scale (mRS) score 3 to 6. The secondary outcomes were an excellent outcome (mRS score 0-1) at 3 months and mRS difference in shift analysis.
RESULTS
In total, 118 UIA patients and 118 matched control patients were identified. The UIA patients were more often current smokers, and their admission systolic blood pressure was higher. The rate of hemorrhagic complications did not differ between the groups. UIAs were not associated with an unfavorable outcome in the conditional logistic regression analysis (odds ratio, 1.41 [95% CI, 0.79-2.54];
CONCLUSIONS
The intravenous thrombolysis-treated stroke patients with UIAs were more often current smokers and had higher systolic blood pressure than the matched patients without UIAs. They were as likely to have unfavorable outcomes at 3 months but seemed less likely to achieve excellent outcomes and were more likely to have higher mRS in shift analysis.

Identifiants

pubmed: 36254706
doi: 10.1161/STROKEAHA.122.040151
pmc: PMC9698101
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3616-3621

Références

Stroke. 2012 Jun;43(6):1524-31
pubmed: 22442178
Stroke. 2012 Sep;43(9):2293-9
pubmed: 22811458
J Stroke Cerebrovasc Dis. 2013 Jul;22(5):639-43
pubmed: 22341666
Brain. 2011 Jul;134(Pt 7):2116-24
pubmed: 21705426
Biometrics. 2000 Jun;56(2):645-6
pubmed: 10877330
Neurology. 2012 Feb 7;78(6):427-32
pubmed: 22311929
PLoS One. 2017 Jun 29;12(6):e0180021
pubmed: 28662192
Stroke. 1988 May;19(5):604-7
pubmed: 3363593
J Stroke Cerebrovasc Dis. 2013 May;22(4):329-33
pubmed: 22018506
Lancet. 1998 Oct 17;352(9136):1245-51
pubmed: 9788453
Stroke. 2006 Dec;37(12):2957-62
pubmed: 17068305
Stroke. 2010 Jul;41(7):1450-8
pubmed: 20538701
Stroke. 2012 Feb;43(2):412-6
pubmed: 22156701
J Neurol Neurosurg Psychiatry. 2021 May;92(5):542-548
pubmed: 33148817
J Stroke. 2016 Sep;18(3):321-327
pubmed: 27488981
Lancet Neurol. 2012 Dec;11(12):1039-47
pubmed: 23122892
Stroke. 1994 Nov;25(11):2220-6
pubmed: 7974549
J Neurol Sci. 2010 Nov 15;298(1-2):42-5
pubmed: 20864121
Cell Biochem Biophys. 2015 Jul;72(3):889-93
pubmed: 25716336
Neurology. 2015 Sep 15;85(11):942-9
pubmed: 26291280
J Am Heart Assoc. 2021 Nov 16;10(22):e022277
pubmed: 34729997
Neurology. 2021 Nov 2;97(18):e1790-e1798
pubmed: 34615686
Neurocrit Care. 2012 Oct;17(2):199-203
pubmed: 22752394
IARC Sci Publ. 1980;(32):5-338
pubmed: 7216345

Auteurs

Jyri J Virta (JJ)

Department of Neurosurgery, Helsinki University Hospital and University of Helsinki, Finland (J.J.V., M.K.).

Daniel Strbian (D)

Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland (D.S., J.P.).

Jukka Putaala (J)

Department of Neurology, Helsinki University Hospital and University of Helsinki, Finland (D.S., J.P.).

Jaakko Kaprio (J)

Institute for Molecular Medicine Finland (FIMM), University of Helsinki (J.K.).

Miikka Korja (M)

Department of Neurosurgery, Helsinki University Hospital and University of Helsinki, Finland (J.J.V., M.K.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH